OBJECTIVE To explore the application of parotid R2* values for evaluating Sjögren syndrome (SS). METHODS Twenty-four consecutive SS patients and 24 sex-matched and age-matched healthy volunteers underwent bilateral parotid 3.0 T magnetic resonance (MR) imaging, including blood oxygenation level dependent sequence. Parotid R2* values of SS patients and volunteers were compared. A receiver oper...

We consider the non-selfadjoint operator H = [ −∆ + μ− V1 −V2 V2 ∆− μ+ V1 ] where μ > 0 and V1, V2 are real-valued decaying potentials. Such operators arise when linearizing a focusing NLS equation around a standing wave. Under natural spectral assumptions we obtain L(R)× L(R)→ L∞(R2)× L∞(R2) dispersive decay estimates for the evolution ePac. We also obtain the following weighted estimate ‖wePa...

BACKGROUND To evaluate the detectability of arterial acute thrombus on R2* map by iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) IQ compared with T2*-weighted imaging (T2*WI). METHODS Twenty-six patients with acute cerebral infarction who underwent R2* map and T2*WI were reviewed. We performed visual assessment of each sequence regarding the ...

OBJECTIVE To evaluate clinical 3.0T magnetic resonance for tracking and quantifying superparamagnetic iron oxide (SPIO)-labeled endothelial progenitor cells (EPCs) in vitro and homing to liver with acute injury in vivo. METHODS The bone marrow-derived EPCs were isolated and cultured for 4 days and examined in vitro for lineage markers. Then the cultured cells were labeled with a ferumoxides-p...

R2 retrotransposable elements exclusively insert into the tandemly repeated rRNA genes, the rDNA loci, of their animal hosts. R2 elements form stable long-term associations with their host, in which all individuals in a population contain many potentially active copies, but only a fraction of these individuals show active R2 retrotransposition. Previous studies have found that R2 RNA transcript...

Despite improvements in the health service and the available treatment means, the outcome of the majority of patients with advanced pancreatic adenocarcinoma, even in the Western world, is disappointing. This fact necessitates invention and development of clinical and laboratory biomarkers that help us detect early enough those patients who have the worst prognosis, and who may benefit or not f...